Ioana R. Preston
Experienced in Lung Metastases

Dr. Ioana R. Preston

Intensive Care Medicine | Pulmonary Medicine
Lahey Clinic Inc
41 Mall Rd, 
Burlington, MA 
Accepting New Patients
Experienced in Lung Metastases
Lahey Clinic Inc
41 Mall Rd, 
Burlington, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ioana Preston is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Burlington, Massachusetts. Dr. Preston is rated as an Experienced provider by MediFind in the treatment of Lung Metastases. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Heart Failure with Preserved Ejection Fraction (HFpEF), Cerebral Hypoxia, and Lung Transplant. Dr. Preston is currently accepting new patients.

Her clinical research consists of co-authoring 89 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Pulmonary Medicine
Licenses
Critical Care Medicine in RI
Hospital Affiliations
Winchester Hospital
Lahey Hospital & Medical Center, Burlington
Northeast Hospital Corporation
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

LAHEY CLINIC INC
41 Mall Rd, Burlington, MA 01805

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

89 Total Publications

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
Journal: The New England journal of medicine
Published: September 30, 2025
Similar Doctors
Payam Aghassi
Distinguished in Lung Metastases
Dr. Payam Aghassi
Pulmonary Medicine | Allergy and Immunology | Intensive Care Medicine
Distinguished in Lung Metastases
Dr. Payam Aghassi
Pulmonary Medicine | Allergy and Immunology | Intensive Care Medicine

Mass Lung And Allergy PC

100 Hospital Rd, Suite 2a, 
Leominster, MA 
 (28.6 miles away)
978-466-2692
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Payam Aghassi is a Pulmonary Medicine specialist and an Allergy and Immunologist in Leominster, Massachusetts. Dr. Aghassi is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Obstructive Sleep Apnea, Gastrostomy, and Endoscopy. Dr. Aghassi is currently accepting new patients.

Distinguished in Lung Metastases
Dr. Jeffrey T. Klenz
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Lung Metastases
Dr. Jeffrey T. Klenz
Pulmonary Medicine | Intensive Care Medicine

Lahey Clinic Inc

41 Mall Rd, Lahey Provider Enrollment Dept, 
Burlington, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Klenz is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Burlington, Massachusetts. Dr. Klenz is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Asthma in Children, Endoscopy, and Gastrostomy. Dr. Klenz is currently accepting new patients.

Distinguished in Lung Metastases
Dr. Robert W. Hallowell
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Lung Metastases
Dr. Robert W. Hallowell
Pulmonary Medicine | Intensive Care Medicine

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (11.0 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Robert Hallowell, MD is a Critical Care Medicine Specialist in Boston, MA and has over 15 years of experience in the medical field. He graduated from Columbia University / College of Physicians And Surgeons in 2007. He is affiliated with medical facilities Beth Israel Deaconess Hospital - Needham and Beth Israel Deaconess Medical Center. Dr. Hallowell is rated as a Distinguished provider by MediFind in the treatment of Lung Metastases. His top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Pneumonia, and Pulmonary Fibrosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Preston's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile